Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05574504
Title Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors AdventHealth
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.